German Federal Court of Justice maintains patent-compulsory license for HIV medicine

Birgit Kramer

The HIV medicine Isentress from Merck may be further distributed.  On 11 July 2017, the German Federal Court of Justice confirmed a decision by the Federal Patent Court (reference X ZB 2/17).  This had determined that the Japanese pharmaceutical company Shionogi must grant the competitor Merck a compulsory license to its European patent (EP 1 Read More

A&O at the Young EPLAW Congress 2017

Jin Ooi

Allen & Overy was represented by Steven Baldwin, Jin Ooi, Rafi Allos and Robyn Trigg at the annual Young EPLAW Congress in Brussels on 24 April 2017.  This year’s Congress covered a number of topics of interest in the Life Sciences, not least the current hot topic of plausibility which Jin Ooi presented on.  Below is a Read More

German Court Issues Compulsory License for Isentress®

Birgit Kramer

On 31 August 2016, the third senate of the Federal Patent Court (ref. no. 3 LiQ 1/16(EP) has issued a compulsory license to Merck for the antiretroviral HIV/AIDS product Isentress®. The compulsory license has been issued in preliminary proceedings and allows the use of the German part of EP 1 422 218 owned by Shionogi Read More

Düsseldorf Court refers to CJEU on applicability of Specific Mechanism during extended SPC term

Birgit Kramer

Last December the Regional Court Düsseldorf referred questions for a preliminary ruling to the CJEU (docket number C-681/16) concerning the applicability of the Specific Mechanism during the term of an SPC extended in accordance with the Paediatric Regulation. Factual background is that the plaintiff owning an SPC for a pharmaceutical product wanted to prevent parallel Read More

Fourth Act amending German Medicinal Law and other Regulations entered into force on 24 December 2016

Birgit Kramer

Regulation (EU) No. 536/2014 on clinical trials with pharmaceuticals for human use (EU Regulation) establishes by directly applicable law binding requirements throughout the European Union (EU) for the approval, the conduct and the monitoring of clinical trials. This made adjustments to the German Medicinal Products Act and the abolition of the German GCP Regulation necessary. Read More